Cullgen's technology focuses on selective degradation of disease-causing proteins, providing scientists with new means to develop novel therapeutic approaches for various diseases.
This new drug discovery platform has the advantage of accelerating new chemical entities (NCEs) into clinical development in a cost and time efficient manner to benefit patients.
Initial drug discovery programs will focus on oncology and expand into areas such as inflammatory and autoimmune diseases.
Privately held Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology.
The company is dedicated to the development of first-in-class NCEs for the treatment of diseases lacking effective therapeutic approaches.
GNI Group focuses on pharmaceutical and medical device businesses with headquarters in Tokyo and subsidiaries in China and the United States.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca